- The US has a high drug prices problem. Obscure but powerful companies called pharmacy-benefit managers (PBMs) have been blamed for it.
- PBMs will now face tough questions from the Senate Finance Committee, which has called in many of their top executives to a Tuesday 9 hearing.
- PBMs have been under attack, so the pressure will be on.
Shadowy but powerful companies that have been blamed for the US’s too-high drug prices are poised to step into the spotlight tomorrow, when their top leaders will testify before the Senate Finance Committee.
Those companies are pharmacy-benefit managers (PBMs), and their very role is to negotiate drug prices down. But drug companies, facing the heat on high drug prices, have rather successfully deflected the blame to PBMs, saying that they also benefit by helping push prices higher. That argument appeared especially persuasive to members of Congress at a prior Senate Finance Committee hearing in late February.
In other words, PBMs shouldn’t be expecting a warm welcome.
Drug companies have “so far run circles around the PBMs on message control,” Stephens analyst Scott Fidel said.
The Tuesday hearing, therefore, “could give the PBMs an opportunity to shift the focus back on the manufacturers for rising Rx prices,” he said.
When it comes to high drug prices, follow the money
US drug prices are the highest in the world, and prices rise each year like clockwork.
And even though there’s been more attention paid to that practice of late, US prices rose again this year on roughly 2,860 drugs, according to Rx Savings Solutions, a software that helps people compare costs of prescription medications.
That’s more than last year, when the prices of roughly 2,550 drugs were increased. But this time, the price hikes seem to have been more spread out, with drugmakers waiting “until March instead of January, to avoid scrutiny,” said Michael Rea, the founder and CEO of Rx Savings Solutions.
It appears that “drug companies were much more conscientious about their tactics to raise prices this year,” Rea said.
These calculations are based on the “list price” of a drug, which a drug company gets to decide. The backlash about high drug prices has been focused on drugmakers because, at the end of the day, prices are their purview.
But PBMs also get involved in pricing, playing different drug companies against eachother to negotiate back-door discounts for health insurers and employers.
Pharmaceutical companies say this is where the process breaks down, because bigger and bigger discounts force them to hike prices, and so on.
PBMs on the defensive
As PBMs have been blamed for the US drug price problem, the face of the PBM industry has been changing.
PBMs are increasingly now in-house, folded into the larger corporate machinery of health insurers or even pharmacy chains. So that’s who you’ll see before the Senate Finance committee on Tuesday.
Set to testify are: health insurer Cigna’s Steve Miller, pharmacy chain CVS’s Derica Rice, health insurer Humana’s William Fleming and UnitedHealth’s John Prince. Those companies all now have their own PBMs, with Cigna buying the largest one, Express Scripts, last year for a whopping $67 billion.
Also planning to be there: Mike Kolar, the interim president and CEO of the lone standalone PBM of the bunch, Prime Therapeutics, which works with Blue Cross and Blue Shield health insurers.
The pressure will be on. Last time a batch of executives were carted before Congress to talk about prescription drug prices, the CEOs of pharmaceutical giants like Merck and Pfizer deftly parlayed blame along to their discount-negotiating peers. Tuesday’s hearing is part of the same series.
A word that will likely rear its head a lot is “rebate,” a type of discount on prescription drugs that has been especially blamed for our current US drug price quandary.
Pharmaceutical executives told senators in February that rebates add to overall list prices for drugs, but patients don’t always benefit from the discounts when picking up prescriptions at the pharmacy.
This argument has been picking up steam, including among the Trump administration, which has even proposed getting rid of them in some government programs.
PBMs, then, “will also need to come ready to explain why rebates are value additive to the U.S. drug pricing model, as this will likely be the most visible public forum they will have” before the final Trump administration rebate rule is released, Fidel said.
- Read more:
- 2 drug giants are feuding over a highly successful new migraine drug, and court documents reveal how profitable the $10 billion market could be
- The top scientist at AveXis told us it got sold to Novartis for $9 billion because of this ‘unique’ strength that could shape the future of gene therapy
- A $23 billion drugmaker and a $2 billion biotech upstart are racing to develop a type of ‘silver bullet’ drug for aggressive cancers that has eluded their industry for 30 years
- Billions of dollars are pouring into gene-therapy startups. Top execs at 3 companies described the biggest challenge the new field faces.